Background: Advances in biologic treatments have led to a new therapeutic frontier for moderate-to-severe psoriasis. Nevertheless, the efficacy of anti-TNFα decreases with time, requiring adjustments to maintain valuable Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) responses. Objectives: To evaluate the efficacy and safety of adalimumab dose escalation (40 mg, subcutaneous, once a week for 24 weeks) in psoriatic adult patients with secondary loss of response (PASI ≥50 to ≤75 or PASI≥75 and DLQI ≥5). Materials and Methods: A multicentre, observational study involving different Italian third-level referral centres for psoriasis enrolled a total of 64 adult patients with moderate-to-severe psoriasis who were treated with adalimumab and experienced a secondary loss of response. Primary end-points were PASI< 75 or PASI ≥50 to ≤ 75 with DLQI ≤ 5, and the secondary end-point was the ability to maintain a therapeutic response, resuming adalimumab every other week. Results: At Week 16 and Week 24, 29/64 (45.3%) and 35/64 (54.6%) responded based on PASI, and mean DLQI was 4.9 and 4.09, respectively. At Week 36 and Week 48, 45.3% and 28.1% patients achieved the second end-point, respectively. No adverse events were recorded except for one patient with recurrent tonsillitis. Conclusion: Adalimumab escalation could be considered in cases with loss of response before switching to alternative biologic therapy.
Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients / Bardazzi, F.; Bigi, L.; Campanati, A.; Conti, A.; Di Lernia, V.; Di Nuzzo, S.; Kaleci, S.; Lasagni, C.; Offidani, A. M.; Giacchetti, A.; Nicolini, M.; Bettacchi, A.; Rosa, L.; Sacchelli, L.. - In: EUROPEAN JOURNAL OF DERMATOLOGY. - ISSN 1167-1122. - 30:2(2020), pp. 159-164. [10.1684/ejd.2020.3751]
|Appare nelle tipologie:||1.1 Articolo su rivista|